Dr Harbarth’s work has garnered several awards. His group is currently conducting several clinical and epidemiological studies to evaluate key questions related to the control of the acquisition, transmission and infection by multidrug-resistant microorganisms and related clinical and health-economic burden. He participates in several ongoing large-scale EU-funded studies (REVERSE, ECRAID, COMBACTE) and coordinated the DRIVE-AB project to address this public health threat.